When Will Genomics Cure Cancer?

Fallows, James; Lander, Eric S.
January 2014
Atlantic;Jan/Feb2014, Vol. 313 Issue 1, p28
An interview is presented with biogeneticist Eric S. Lander which focuses on how genetic advances impact medical treatment. When asked about the future of genomics research, Lander comments on the developing categorization of disease genes. Other topics covered include the development of cancer-treating drugs, treatment of psychiatric diseases, and research funding.


Related Articles

  • Microbiome: An encrypted growth signature. Attar, Naomi // Nature Reviews Microbiology;Sep2015, Vol. 13 Issue 9, p527 

    The article presents the research conducted by researcher Korem T. on measuring the number of copies of a sequence that genomic sites at each genomic site for every species in metagenome.

  • HER2-Positive Breast Cancer, Intrinsic Subtypes, and Tailoring Therapy. Ellis, Matthew James // JNCI: Journal of the National Cancer Institute;Aug2014, Vol. 106 Issue 8, p1 

    The article explores efforts to investigate the effectiveness of targeting the HER2 oncogen among patients with breast cancer, a controversial therapy due to concerns over the use of carboplatin versus antha-cycline-based regimens. Topics discussed include the use of ER+, HER2-targeting therapy...

  • Drugging cancer genomes. Workman, Paul; Al-Lazikani, Bissan // Nature Reviews Drug Discovery;Dec2013, Vol. 12 Issue 12, p889 

    The article focuses on the importance of sequencing of cancer genomes for understanding the pathogenesis of human malignancies. It informs that the sequencing of cancer genome evolved the development of two kinase inhibitors BRAF kinase inhibitor vemurafenib and the anaplastic lymphoma kinase...

  • Labeling and Biological Evaluation of 99mTc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer. Calzada, Victoria; Garcia, Fernanda; Fernández, Marcelo; Porcal, Williams; Quinn, Thomas; Alonso, Omar; Gambini, Juan Pablo; Cabral, Pablo // World Journal of Nuclear Medicine;Jan2013, Vol. 12 Issue 1, p27 

    The amplification of HER2 gene has been described in several tumor types, mainly breast cancer with a subsequent increase in HER2 protein expression. Trastuzumab is a humanized monoclonal antibody that recognizes selectively the HER2 extracellular domain. The objective of the present work was to...

  • Science Across the Borders. Hobson, Katherine // U.S. News & World Report;10/30/2006, Vol. 141 Issue 16, p89 

    The article presents an interview with genetic researcher Eric Lander, head of the Broad Institute of Harvard University and the Massachusetts Institute of Technology. He discusses why scientists would want to work on the Human Genome Project, which he helped steer to completion. Lander also...

  • HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. IENI, A.; BARRESI, V.; GIUFFRÈ, G.; CARUSO, R. A.; LANZAFAME, S.; VILLARI, L.; SALOMONE, E.; ROZ, E.; CABIBI, D.; FRANCO, V.; CERTO, G.; LABATE, A.; NAGAR, C.; MAGLIOLO, E.; BROGGI, B.; FAZZARI, C.; ITALIA, F.; TUCCARI, G. // Oncology Letters;2013, Vol. 6 Issue 6, p1591 

    According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate of HER2 positivity to be markedly varied. To...

  • 11 years ago: The draft human genome.  // Nature;9/6/2012, Vol. 489 Issue 7414, p54 

    The article offers insights from various people on the draft of human genome in 2001 such as one from David Baltimore who said that it is still be a challenged to understand the complexity of human and one from Peer Bork and Richard Copley that the draft will help researchers study genes.

  • PERSONALISED THERAPY FOR MELANOMA. Broziĉ, Jasmina Mariĉ; Ðakoviĉ, Nikola // Rad Hrvatske Akademije Znanosti i Umjetnosti. Medicinske Znanost;2014, Vol. 520 Issue 40, p51 

    In the therapy of metastatic melanoma, prior to 2011 the only approved treatment option were dacarbazine and interleukin-2, with a small percentage of patients with good response; no study involving these agents had shown an improvement in overall survival. Researches in the last decades have...

  • Cancer Cause Also a Cure?  // Australasian Science;Apr2011, Vol. 32 Issue 3, p9 

    The article reports on the results of a study that was conducted by doctors Laurent Pangon and Maija Kohonen-Corish in 2011 concerning the role of the MCC gene in response to radiotherapy and chemotherapy for patients with colorectal cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics